Can I Take Vitamin D with Belsomra (Suvorexant)?

What Is Suvorexant and How Does It Work?

Suvorexant blocks orexin receptors OX1R and OX2R in the brain, reducing the wake-promoting signal that orexin neuropeptides send. The FDA approved it in August 2014 under the brand name Belsomra for adults with insomnia characterized by difficulty falling or staying asleep. The prescribing label lists the approved doses as 10 mg and 20 mg taken no more than once per night, within 30 minutes of bedtime.

CYP3A4: The Enzyme That Governs Suvorexant Exposure

Suvorexant is cleared almost entirely by CYP3A4-mediated hepatic metabolism. Strong CYP3A4 inhibitors, such as ketoconazole or clarithromycin, can double or triple suvorexant plasma exposure. Strong inducers, such as rifampin, can cut exposure dramatically. This metabolic pathway is the lens through which any co-administered substance must be evaluated.

Orexin Receptor Pharmacology and Supplement Interactions

Vitamin D has no known binding affinity for OX1R or OX2R. There is no pharmacodynamic mechanism by which standard vitamin D supplementation would amplify sedation, alter sleep architecture, or change suvorexant's binding kinetics. A 2019 receptor-binding review in Frontiers in Pharmacology confirms that fat-soluble vitamins are not orexin receptor ligands.

How Is Vitamin D Metabolized?

Vitamin D (cholecalciferol, D3) is converted in the liver to 25-hydroxyvitamin D (25-OH-D) by CYP27A1, then in the kidney to the active form 1,25-dihydroxyvitamin D (calcitriol) by CYP27B1. Inactivation proceeds via CYP24A1. This three-enzyme cascade is well-characterized in the NIH Office of Dietary Supplements fact sheet for health professionals.

Does Vitamin D Touch CYP3A4?

At supplementation doses of 1,000 to 4,000 IU daily, vitamin D does not produce meaningful CYP3A4 inhibition or induction. A PubMed-indexed pharmacokinetic analysis (Schmiedlin-Ren et al., 1997) showed that supraphysiologic vitamin D concentrations can weakly induce CYP3A4 in intestinal cells in vitro, but the concentrations required far exceed what standard oral supplementation achieves in plasma. No clinical drug-interaction study has demonstrated a measurable change in CYP3A4 substrate clearance at doses below 10,000 IU/day.

Fat-Soluble Vitamin D and Absorption Timing

Because vitamin D is fat-soluble, its absorption depends on dietary fat co-ingestion, not on the timing of suvorexant. Suvorexant absorption is not fat-dependent, and the two compounds do not compete for intestinal transport proteins. Taking them at the same time or hours apart produces the same clinical outcome.

Is There a Known Drug Interaction Between Suvorexant and Vitamin D?

No. The FDA prescribing information for Belsomra does not list vitamin D among interacting substances. The interaction database maintained by the National Institutes of Health MedlinePlus drug interaction tool similarly records no interaction between suvorexant and cholecalciferol or ergocalciferol.

Pharmacokinetic Interaction Risk: Low

A formal drug-interaction classification assigns risk on the basis of (1) shared enzymatic pathways and (2) the magnitude of any enzyme modulation. Suvorexant uses CYP3A4. Vitamin D at 1,000 to 4,000 IU uses CYP27A1 and CYP27B1 as primary enzymes. The enzymatic overlap is negligible, making the pharmacokinetic interaction risk low by standard classification criteria.

Pharmacodynamic Interaction Risk: None Established

Both substances affect the central nervous system tangentially, but through entirely separate mechanisms. Suvorexant produces sedation by blocking orexin. Vitamin D modulates calcium homeostasis, bone metabolism, and immune signaling through the vitamin D receptor (VDR), a nuclear hormone receptor. A 2020 review in the Journal of Steroid Biochemistry and Molecular Biology documented VDR expression in multiple brain regions but found no evidence that VDR activation changes orexinergic signaling or sedative drug response at physiologic vitamin D concentrations.

Vitamin D Deficiency and Insomnia: Why This Matters Clinically

Patients prescribed suvorexant have insomnia by definition. Vitamin D deficiency is common in this population. A cross-sectional analysis published in the Journal of Clinical Sleep Medicine (McCarty et al., 2012, N=81) found that 25-OH-D levels below 20 ng/mL were significantly associated with shorter sleep duration and poorer sleep quality. Correcting deficiency may modestly improve baseline sleep, though it does not replace pharmacotherapy in established insomnia disorder.

Prevalence of Vitamin D Deficiency

The CDC's second National Report on Biochemical Indicators of Diet and Nutrition estimated that approximately 32% of the U.S. Population has 25-OH-D levels below 20 ng/mL, the threshold the Endocrine Society defines as deficiency. Among adults over 65, who represent a large share of suvorexant users, deficiency rates may exceed 40%.

Endocrine Society Targets

The Endocrine Society Clinical Practice Guideline on Vitamin D Deficiency (Holick et al., 2011) defines vitamin D sufficiency as a 25-OH-D level of 30 ng/mL or above. The guideline recommends 1,500 to 2,000 IU/day for most adults to maintain sufficiency, and up to 10,000 IU/day as the tolerable upper limit in healthy adults. The authors state: "We recommend that adults aged 19 to 50 years receive at least 600 IU of vitamin D daily to maximize bone health and muscle function. Adults aged 50 to 70 years require at least 600 IU daily, and those over 70 require at least 800 IU daily."

Edge Cases: When Extra Caution Is Warranted

Most patients taking Belsomra at 10 or 20 mg with a standard vitamin D supplement face no meaningful risk. A small number of clinical scenarios merit closer attention.

Severe Hepatic Impairment

Suvorexant is contraindicated in severe hepatic impairment per the Belsomra prescribing label. The liver also performs the first hydroxylation step for vitamin D via CYP27A1. In patients with Child-Pugh Class C cirrhosis, both suvorexant clearance and vitamin D activation may be impaired simultaneously, though the two impairments are independent rather than additive. Physicians managing these patients should check 25-OH-D and adjust replacement doses accordingly rather than restricting supplementation.

Supratherapeutic Vitamin D Doses (>10,000 IU/day)

At doses above 10,000 IU/day sustained over weeks, vitamin D can cause hypercalcemia. A 2019 case series in JAMA Internal Medicine documented hypercalcemia and hypercalciuria in patients ingesting 50,000 IU/day or more. Hypercalcemia at severe levels alters neuronal excitability and can theoretically compound CNS-depressant effects of any sedative drug, including suvorexant. This remains a theoretical concern with no published clinical reports specific to suvorexant. Standard supplementation doses (1,000 to 4,000 IU) do not cause hypercalcemia in patients with normal renal function.

Concurrent CYP3A4 Inhibitors

Some patients take suvorexant alongside azole antifungals, macrolide antibiotics, or HIV protease inhibitors, all of which are strong CYP3A4 inhibitors. Adding vitamin D in this context does not change the interaction picture. The CYP3A4 inhibitor remains the dominant concern. The Belsomra label explicitly states that suvorexant should not be used with strong CYP3A4 inhibitors, regardless of what other supplements the patient takes.

Practical Dosing and Monitoring Recommendations

The table below organizes clinical decision points for a patient taking Belsomra who wants to add or continue vitamin D supplementation.

| Clinical Variable | Recommendation | |---|---| | Standard adult dose of vitamin D (1,000 to 4,000 IU/day) | Take freely; no dose-separation or interaction monitoring required | | Vitamin D dose >4,000 IU/day | Check 25-OH-D and serum calcium at baseline and after 3 months | | Severe hepatic impairment | Suvorexant use is contraindicated; manage vitamin D independently | | Concurrent strong CYP3A4 inhibitor | Interaction concern is with the inhibitor, not vitamin D; follow label guidance | | Renal insufficiency (eGFR <30 mL/min/1.73m²) | Activated vitamin D (calcitriol) may be preferred over cholecalciferol; nephrology consultation appropriate | | Age over 65 | Screen 25-OH-D annually; deficiency common in this suvorexant-using demographic |

What Time of Day Should I Take Each?

Suvorexant should be taken within 30 minutes of bedtime, on an empty stomach or after a light meal. Vitamin D is best absorbed with a fat-containing meal, which for most people falls at lunch or dinner. Taking vitamin D at dinner and suvorexant at bedtime is a simple and clinically reasonable routine. There is no evidence that simultaneous ingestion causes harm, but separating them by a few hours with food maximizes vitamin D absorption without any pharmacokinetic consequence for suvorexant.

Monitoring 25-OH-D Levels

The Endocrine Society guideline recommends checking serum 25-OH-D to confirm sufficiency rather than dosing by weight alone. A baseline draw before starting supplementation, followed by a repeat level 3 months after initiating a new dose, provides the data needed to confirm adequacy without risking accumulation. The target range is 30 to 50 ng/mL for most adults.

What the Guidelines Say: Direct Quotations

The 2014 FDA-approved Belsomra prescribing information states: "Suvorexant is a CYP3A substrate. Avoid use with strong CYP3A inhibitors. Use with moderate CYP3A inhibitors requires dose adjustment." Vitamin D is not mentioned because it is not a CYP3A modulator at therapeutic doses.

The Endocrine Society Clinical Practice Guideline (Holick et al., 2011) recommends: "Screening for vitamin D deficiency in individuals at risk for deficiency. For those who are vitamin D-deficient, we suggest treatment with 50,000 IU of vitamin D2 or vitamin D3 once a week for 8 weeks or its equivalent of 6,000 IU of vitamin D2 or vitamin D3 daily to achieve a blood level of 25(OH)D above 30 ng/mL, followed by maintenance therapy of 1,500 to 2,000 IU/day."

Suvorexant's Full Interaction Profile: Context for Vitamin D

Understanding what does interact with suvorexant clarifies why vitamin D does not. The prescribing label identifies the following drug classes as meaningful:

• Strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir): contraindicated
• Moderate CYP3A4 inhibitors (diltiazem, verapamil, fluconazole): use 5 mg starting dose
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): avoid combination
• CNS depressants (alcohol, benzodiazepines, opioids): additive sedation risk

Vitamin D fits none of these categories. A 2021 pharmacokinetic review in Clinical Pharmacokinetics confirmed that fat-soluble vitamins A, D, E, and K do not produce clinically significant CYP3A4 modulation at standard dietary or supplementation doses.

Sleep, Vitamin D, and the Orexin System: Emerging Research

Sleep-wake regulation and vitamin D status intersect through pathways outside the orexin system. VDR (vitamin D receptor) expression has been detected in the hypothalamic suprachiasmatic nucleus, which governs circadian rhythm. Low 25-OH-D has been associated with reduced sleep duration in observational studies. A randomized controlled trial by Majid et al. (2018, N=89) found that vitamin D3 supplementation at 50,000 IU every two weeks for 8 weeks improved Pittsburgh Sleep Quality Index scores by a mean of 2.4 points compared to placebo (P<0.05).

This does not mean vitamin D replaces suvorexant. The Majid trial enrolled patients with vitamin D deficiency and sleep disorders but not necessarily DSM-5 insomnia disorder. The two interventions address different physiologic targets and can be used together without conflict.